These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20936439)

  • 21. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
    Seoane-Vazquez E; Rodriguez-Monguio R; Hansen R
    Clin Drug Investig; 2016 Apr; 36(4):281-92. PubMed ID: 26818406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products.
    Strauch S; Jantratid E; Dressman JB
    J Pharm Pharmacol; 2009 Mar; 61(3):331-7. PubMed ID: 19222905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules.
    Tan Y; Si X; Zhong L; Feng X; Yang X; Huang M; Wu C
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1669-77. PubMed ID: 27066697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microencapsulation of dye- and drug-loaded particles for imaging and controlled release of multiple drugs.
    Khung YL; Li Lee W; Chui KL; Liu Y; Lim MP; Huang CL; Loo SC
    Adv Healthc Mater; 2012 Mar; 1(2):159-63. PubMed ID: 23184718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of in vitro-in vivo correlations (IVIVC) to regulatory agencies.
    Malinowski HJ
    Adv Exp Med Biol; 1997; 423():261-8. PubMed ID: 9269502
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA moves closer to new requirements for NTI drugs.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report.
    Chen ML; Shah VP; Ganes D; Midha KK; Caro J; Nambiar P; Rocci ML; Thombre AG; Abrahamsson B; Conner D; Davit B; Fackler P; Farrell C; Gupta S; Katz R; Mehta M; Preskorn SH; Sanderink G; Stavchansky S; Temple R; Wang Y; Winkle H; Yu L
    Eur J Pharm Sci; 2010 May; 40(2):148-53. PubMed ID: 20347972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of data base structure in a successful in vitro-in vivo correlation for pharmaceutical products.
    Roudier B; Davit B; Schütz H; Cardot JM
    AAPS J; 2015 Jan; 17(1):24-34. PubMed ID: 25387995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 34. The evolving landscape of drug products containing nanomaterials in the United States.
    D'Mello SR; Cruz CN; Chen ML; Kapoor M; Lee SL; Tyner KM
    Nat Nanotechnol; 2017 Jul; 12(6):523-529. PubMed ID: 28436961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing bioequivalence of generic modified-release antiepileptic drugs.
    Johnson EL; Chang YT; Davit B; Gidal BE; Krauss GL
    Neurology; 2016 Apr; 86(17):1597-604. PubMed ID: 27016518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory considerations for generic or biosimilar low molecular weight heparins.
    García-Arieta A; Blázquez A
    Curr Drug Discov Technol; 2012 Jun; 9(2):137-42. PubMed ID: 21838658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
    Paixão P; Gouveia LF; Morais JA
    Eur J Pharm Biopharm; 2012 Feb; 80(2):410-7. PubMed ID: 22108491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
    Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of In Vitro-In Vivo Correlations in Generic Drug Development: Case Studies.
    Kaur P; Jiang X; Duan J; Stier E
    AAPS J; 2015 Jul; 17(4):1035-9. PubMed ID: 25896303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2020: A Record Year for Drug Approvals.
    Losben NL
    Sr Care Pharm; 2021 Apr; 36(4):174-175. PubMed ID: 33766189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.